Abstract:A large number of β-adrenergic receptor (β-AR) agonists and antagonists are widely used in the treatment of cardiovascular diseases and other diseases. Nonetheless, it remains unclear whether these commonly used β-AR drugs can activate downstream β- arrestin-biased signaling pathways. The objective of this study was to investigate β-arrestin2 recruitment effects of β-AR agonists and antagonists that were commonly used in clinical practice. We used TANGO (transcriptional activation following arrestin translocation) assay to detect the β-arrestin2 recruitment by β-AR ligands in HEK293 cell line (HTLA cells) stably transfected with tetracycline transactivator protein (tTA) dependent luciferase reporter and β-arrestin2-TEV fusion gene. Upon activation of β-AR by a β-AR ligand, β-arrestin2 was recruited to the C terminus of the receptor, followed by cleavage of the G protein-coupled receptors (GPCRs) fusion protein at the TEV protease-cleavage site. The cleavage resulted in the release of tTA, which, after being transported to the nucleus, activated transcription of the luciferase reporter gene. The results showed that β-AR non-selective agonists epinephrine, noradrenaline and isoprenaline all promoted β-arrestin2 recruitment at β1-AR and β2-AR. β1-AR selective agonists dobutamine and denopamine both promoted β-arrestin2 recruitment at β1-AR. β2-AR selective agonists procaterol and salbutamol promoted β-arrestin2 recruitment at β2-AR. β-AR non-selective antagonists alprenolol and pindolol promoted β-arrestin2 recruitment at β1-AR. β1-AR selective antagonists celiprolol and bevantolol showed β-arrestin2 recruitment at β1-AR. β2-AR selective antagonists butoxamine showed β-arrestin2 recruitment at β1-AR. These results provide some clues for the potential action of β-AR drugs, and lay a foundation for the screening of β-arrestin-biased β-AR ligands.

Β-Arrestin Signaling and Regulation of Transcription

Phospho-selective Mechanisms of Arrestin Conformations and Functions Revealed by Unnatural Amino Acid Incorporation and 19F-NMR

Distinct Conformations of GPCR–β-arrestin Complexes Mediate Desensitization, Signaling, and Endocytosis

A Nuclear Function of β-Arrestin1 in GPCR Signaling: Regulation of Histone Acetylation and Gene Transcription

The role and mechanism of β-arrestin2 in signal transduction

Classical and new roles of β-arrestins in the regulation of G-PROTEIN-COUPLED receptors

Β-Arrestin 2 Negatively Regulates Toll-like Receptor 4 (Tlr4)-Triggered Inflammatory Signaling Via Targeting P38 MAPK and Interleukin 10.

β-Arrestins 1 and 2 are critical regulators of inflammation

Β-Arrestin2 Recruitment by Β-Adrenergic Receptor Agonists and Antagonists

β-Arrestin-1 directly interacts with Gαs and regulates its function

Insight into the regulatory mechanism of β-arrestin2 and its emerging role in diseases

Involvement of Β-Arrestins in Cancer Progression

Β-Arrestins: Multifunctional Signaling Adaptors in Type 2 Diabetes.

β-arrestin2: an emerging player and potential therapeutic target in inflammatory immune diseases

Location-biased β-arrestin conformations direct GPCR signaling

Beta-Arrestin 2 Functions As A G-Protein-Coupled Receptor-Activated Regulator Of Oncoprotein Mdm2

Therapeutic Potential of Targeting ß-Arrestin

Functional Specialization of Β-Arrestin Interactions Revealed by Proteomic Analysis

Β-Arrestin-1 Protein Represses Adipogenesis and Inflammatory Responses Through Its Interaction with Peroxisome Proliferator-activated Receptor-γ (Pparγ)

Β-Arrestins As Potential Therapeutic Targets for Alzheimer’s Disease

Signal transduction at GPCRs: Allosteric activation of the ERK MAPK by β-arrestin